Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report

Sohayb Faleh; Tanya Odisho; Florence Lebel-Guay; Mikaël L. Soucisse; Jose Ferreira; Sara V. Soldera; Lucas Sideris

doi:10.12659/AJCR.949777

09 November 2025 : Case report Canada

Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Sohayb Faleh^{ABCDEF 1,2,3}, Tanya Odisho^{BDEF 3}, Florence Lebel-Guay^{BEF 1}, Mikaël L. Soucisse

^{ABD 1}, Jose Ferreira^{BD 4}, Sara V. Soldera

^{ABCDEF 5}, Lucas Sideris^{ABCDEF 1*}

DOI: 10.12659/AJCR.949777

Am J Case Rep 2025; 26:e949777

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Restaging CT scan abdomen/pelvis after immunotherapy treatment, demonstrating partial disease response and no extra-abdominal metastases (A, B) and decreased pelvic free fluid (C, red arrow).

Back to the Article

Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report

Your Privacy